News

Prior to joining MacroGenics, Mr Risser served as senior director of business development at Johnson & Johnson Pharmaceuticals, which he joined in 2003. Before Johnson & Johnson, Mr

Lannett is currently conducting an internal and external search for a permanent CFO. Prior to joining Lannett, Mr Ruck served as corporate controller of Optium. Earlier, Mr Ruck

Dr Boehm is currently employed as vice president of product development at Actavis Pharmaceuticals and is expected to commence employment with Acura in May 2009. Andy Reddick, president

The Biotechnology Industry Organization (BIO) President James Greenwood said: Arizona’s scientists and citizens are missing out on a potential lucrative source of research funds and medical benefits because

For the year 2008, cost of sales increased by $161,917. The increase is related to the increased sales during the year 2008. Sales and Marketing Expenses For the

“Diagnostic tests add value to the health care system by enabling more accurate and targeted treatments for patients and by detecting disease earlier when successful treatment can be

NeurogesX, a biopharmaceutical company, has reported a net loss attributable to common stockholders of $4.79m, or $0.27 per share, for the fourth quarter of 2008, compared to a

Eli Lilly and Company has reported that the FDA has approved a new indication for Symbyax. Symbyax is now reported to be the first drug approved by the

SemBioSys Genetics, a Canadian biotechnology company, has reported positive preliminary results of its first ‘in-man’ clinical study of SBS-1000, a recombinant human insulin manufactured using its proprietary platform.